Drug firm Lupin Tuesday said it has received four observations in the establishment inspection report (EIR) given by the US health regulator following the closure of pharmacovigilance inspection. "The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin's marketed products worldwide. The inspection closed with four observations," the company said in a regulatory filing. Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the post-marketing adverse drug experience (PADE) inspection, indicating successful closure of the inspection, the filing added. The inspection was conducted at its global pharmacovigilance group DSRM (Drug Safety & Risk Management) based out of Mumbai between January 14-18, 2019, Lupin said. The USFDA issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection following the closure of the inspection. Shares of Lupin Ltd were trading
from Latest News http://bit.ly/2Q8gc20
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P
Home
Business
Business News
Business Standard
Latest News
Lupin gets four observations from USFDA for pharmacovigilance inspection
Tuesday, May 14, 2019
Related Posts:
More people displaced due to climate disasters than conflicts in 2020More than 55 million people had been forced to move by the end of 2020… Read More
iQOO 7 Legend review: Beats rivals with stunning design, flagship specsWith neat looks and spectacular specifications, the iQOO 7 Legend stan… Read More
EU to cut air links with Belarus after Ryanair flight diversion incidentLeaders of the European Union (EU) member states on Monday agreed to c… Read More
New Nasa earth system observatory to help address, mitigate climate changeNasa will design a new set of Earth-focused missions to provide key in… Read More
0 comments: